Cardiovascular Disease Prognostic Models in Latin America and the Caribbean

A Systematic Review

Rodrigo M. Carrillo-Larco1, Carlos Altez-Fernandez1, Niels Pacheco-Barrios1, Claudia Bambs1, Vilma Irazola1, J. Jaime Miranda1,5, Goodarz Danaei6, Pablo Perez6

London, UK; Lima, Peru; Santiago, Chile; Buenos Aires, Argentina; and Boston, MA, USA

ABSTRACT

Background: Cardiovascular prognostic models guide treatment allocation and support clinical decisions. Whether there are valid models for Latin American and Caribbean (LAC) populations is unknown.

Objective: This study sought to identify and critically appraise cardiovascular prognostic models developed, tested, or recalibrated in LAC populations.

Methods: The systematic review followed the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) framework (PROSPERO [International Prospective Register of Systemic Reviews]: CRD42018096553). Reports were included if they followed a prospective design and presented a multivariable prognostic model; reports were excluded if they studied symptomatic individuals or patients. The following search engines were used: EMBASE, MEDLINE, Scopus, SciELO, and LILACS. Risk of bias assessment was conducted with PROBAST (Prediction model Risk Of Bias ASsessment Tool). No quantitative summary was conducted due to large heterogeneity.

Results: From 2,506 search results, 8 studies (N = 130,482 participants) were included for qualitative synthesis. We could not identify any cardiovascular prognostic model developed for LAC populations; reviewed reports evaluated available models or conducted a recalibration analysis. Only 1 study included a Caribbean population (Puerto Rico); 3 studies were retrieved from Chile; 2 from Argentina, Brazil, Colombia, and Uruguay; and 1 from Mexico. Four studies included population-based samples, and the other 4 included people affiliated to a health facility (e.g., prevention clinics). Most studied participants were older than 50 years, and there were more women in 5 reports. The Framingham model was assessed 6 times, and the American College of Cardiology/American Heart Association pooled equation was assessed twice. Across the prognostic models assessed, calibration varied widely from one population to another, showing great overestimation particularly in some subgroups (e.g., highest risk). Discrimination (e.g., C-statistic) was acceptable for most models; for Framingham it ranged from 0.66 to 0.76. The American College of Cardiology/American Heart Association pooled equation showed the best discrimination (0.78). That there were few outcome events was the most important methodological limitation of the identified studies.

Conclusions: No cardiovascular prognostic models have been developed in LAC, hampering key evidence to inform public health and clinical practice. Validation studies need to improve methodological issues.

Cardiovascular diseases are the leading cause of death and disability, both globally and in Latin America and the Caribbean (LAC) [1,2]. These trends can be improved through different strategies, modifying the distribution of risk factors in the population as a whole, that is, a population-based prevention approach (e.g., sugar taxes), and through an overall risk-based prevention approach [3,4]. It has been argued that the latter is cost-effective and maximizes resources allocation (e.g., treatment) to those who most need them with minimal harm [5,6]. However, risk-based prevention needs accurate prognostic tools to identify the target population.

There is some evidence that available cardiovascular risk prediction equations do not perform well in LAC [7], where cardiovascular key risk factors such as diabetes seem to have different strength of association with cardiovascular events [8]. Therefore, it becomes necessary to identify which available equations have undergone local scrutiny and whether new local tools have been developed. Even though there have been efforts to summarize cardiovascular prognostic models [9,10], they did not include studies written in Spanish or search engines with large LAC influence, hence reporting no results from LAC [10].

R. M. Carrillo-Larco is supported by a Wellcome Trust International Training Fellowship (214185/Z/18/Z). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

This study was funded by Strategic Award, Wellcome Trust-Imperial College Centre for Global Health Research (100693/Z/12/Z) and Imperial College London Wellcome Trust Institutional Strategic Support Fund (Global Health Clinical Research Training Fellowship: 294834/2/16/Z) LS F grants.

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ghart.2019.03.001.

From the *Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; †Cronicas Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru; ‡Faculty of Medicine “Alberto Hurtado”, Universidad Peruana Cayetano Heredia, Lima, Peru; ¶Department of Public Health and Advanced Center for Chronic Diseases (ACCIDIS), Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; #Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; ¶Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA; and the R Centre for Global Chronic Conditions, London School of Hygiene and Tropical Medicine, London, UK. Correspondence: R. M. Carrillo-Larco (r.carrillo-larco@imperial.ac.uk).

GLOBAL HEART © 2019 The Authors. Published by Elsevier Ltd. on
Therefore, whether available cardiovascular prognostic models have been tested or a new model has been derived in LAC, remains largely unknown. Consequently, we conducted a systematic review to summarize and critically appraise studies evaluating or generating prognostic models for cardiovascular outcomes conducted in LAC. In so doing, we provide a comprehensive list of available prognostic models, their strengths and limitations, as well as recommendations and identification of research gaps to be addressed to improve cardiovascular prevention in LAC.

METHODS

Study design

The protocol for this systematic review of the literature was registered at PROSPERO (International Prospective Register of Systematic Reviews) (CRD42018096553) [11]. This work adheres to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (see the PRISMA Checklist in the Online Appendix) and CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) framework [12-14]. Following the CHARMS framework, we sought prognostic models that predict the risk of having a cardiovascular (nonfatal and fatal) outcome in a pre-defined period of time to be used in the general population to guide prevention or treatment recommendations (Table 1). We exclusively focused on reports that included LAC populations.

Eligibility criteria

Inclusion criteria comprised the following: 1) The overall study design had to be prospective; this included studies that turned into prospective cohorts, even though they were not originally designed as such. For example, a cross-sectional survey/study in which participants were looked up in death/hospital registries after some years. 2) The study reported a multivariable (i.e., at least 2 variables or predictors) model to predict the risk of developing a nonfatal and/or fatal cardiovascular event (e.g., stroke, myocardial infarction, and death) in an individual of the general population. On the other hand, exclusion criteria included the following: 1) the study population targeted symptomatic (e.g., emergency care) or only patients with specific pathologies (e.g., chronic kidney disease); and 2) the study population targeted people who, by the time of the baseline assessment, had already experienced a cardiovascular outcome (e.g., stroke).

Information sources

On July 15, 2018, a systematic search of publications was conducted using 5 search engines: Ovid (EMBASE and MEDLINE), Scopus, SciELO and LILACS; the latter 2 are LAC-specific. The search terms were based on a recent systematic review, which only included EMBASE, MEDLINE, and articles in English [10]. In addition, terms regarding LAC countries were included (i.e., country names). No additional filters (e.g., language or publication year) were set. The list of search terms is presented in the Online Appendix.

Search

Before titles and abstract screening, 2 reviewers (RMC-L and NP-B) agreed on a standard approach. Two random samples of 50 search results were selected for training purposes. Reviewers screened these titles and abstracts and the inter-rater agreement and kappa estimator were computed, aiming for an inter-rater agreement of at least 90% (see “Training of reviewers” in the Online Appendix). After this standardization process, the 2 reviewers (RMC-L and NP-B) screened all titles and abstracts following the pre-specified framework and selection criteria. Discrepancies were solved by a third reviewer independently (CA-F). After the title and abstract selection, full text of selected reports was sought and analyzed by 2 reviewers (RMC-L and CA-F) following the same above-mentioned selection criteria; discrepancies were solved by consensus between these reviewers. These selection processes—titles and abstracts as well as full texts—were conducted using the online tool Rayyan-a [15]. With the final list of studies to be included for qualitative synthesis, 2 reviewers (RMC-L and CA-F) extracted relevant information in a pre-specified form developed by the authors based on the CHARMS framework [13,14]. Meta-analysis was not conducted because of the large heterogeneity among studies. Results were summarized qualitatively and relevant point estimates (e.g., C-statistics) are presented.

Risk of bias

The PROBAST tool for risk of bias appraisal was used [16-18]. This tool was applied by 1 reviewer (RMC-L). The PROBAST (Prediction model Risk Of Bias AAssessment

| TABLE 1. Review framework according to the CHARMS checklist |
|-------------------|-----------------|
| **Item**          | **Criterion**   |
| Prognostic or diagnostic | Prognostic, i.e., future events. |
| Scope             | Prognostic models to inform clinicians (and general population) about the risk of a person to develop a nonfatal/fatal cardiovascular event in a pre-defined period. |
| Type of prediction models | Prognostic models with and/or without external validation. |
| Prediction target population | General population, men and women. |
| Outcome of interest | Any nonfatal or fatal cardiovascular event, including myocardial infarction, stroke, or cardiovascular death; these outcomes could have been studied independently or as a composite endpoint. |
| Prediction period | Any (e.g., 10 yrs). |
| Intended moment to apply the prediction tool | Prognostic tool to be used in primary prevention to assess cardiovascular risk and thus guide prevention/treatment. |

CHARMS, Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies.
Tool) tool has been designed to assess risk of bias of multivariate prognostic models in 4 domains: 1) participants; 2) predictors; 3) outcome; and 4) analysis. The criteria within each domain have 5 possible answers: yes; probably yes; probably no; no; and no information. A positive answer suggests no risk of bias. The domains had 3 potential outcomes: low; high; or unclear risk of bias.

RESULTS

Study selection

The search retrieved 2,506 results. After removing duplicates, 2,420 titles and abstracts were screened, and of these 2,403 were excluded. Of the 17 reports studied in detail, 8 reports (N = 130,482 participants) were selected for qualitative synthesis (see the Extraction form in the Online Appendix). There was the same number of reports and studies.

Tool) tool has been designed to assess risk of bias of multivariate prognostic models in 4 domains: 1) participants; 2) predictors; 3) outcome; and 4) analysis. The criteria within each domain have 5 possible answers: yes; probably yes; probably no; no; and no information. A positive answer suggests no risk of bias. The domains had 3 potential outcomes: low; high; or unclear risk of bias.

RESULTS

Study selection

The search retrieved 2,506 results. After removing duplicates, 2,420 titles and abstracts were screened, and of these 2,403 were excluded. Of the 17 reports studied in detail, 8 reports (N = 130,482 participants) were selected for qualitative synthesis (see the Extraction form in the Online Appendix). There was the same number of reports and studies.

Study characteristics

Five of the 8 reports were published in Latin-American journals [19-23], with 3 of them written in Spanish [19,22,23]. The oldest report was published in 2001 [24] and the newest ones in 2018 [20,25]. Six reports were conducted in 1 country only [19,21-24,26], and there were 2 multicountry efforts including Argentina, Chile, and Uruguay [20], as well as Argentina, Brazil, Chile, and Colombia (Fig. 1) [25]. The country that has been mostly included in this review was Chile (3 of 8) [19,20,25]; Argentina, Brazil, Colombia, and Uruguay were studied in 2 reports [20,22,23,25,26]; Puerto Rico [24] and Mexico [21] were included in 1 report (Fig. 1). None of the reviewed studies reported adherence to the TRIPOD (Transparent Reporting of a Multivariable Prognostic Model for Individual Prognosis or Diagnosis) statement.

Four studies collected baseline information in the 2000s [19,20,25,26], 3 in the 1990s [21-23], and 1 between 1965 and 1968 [24]. One-half of the selected studies

---

**FIGURE 1. Discrimination estimates for each prognostic model by country.** Confidence intervals, when reported, are presented in Online Table 1. In Acevedo [19], the outcome was cardiovascular mortality (did not include nonfatal events). Brown dots represent studies conducted with populations in 1 country alone, and orange dots are for multicountry studies. PROCAM is a prognostic model for men, the “PROCAM (sex)” indicates the adjusted model so that it can be used for men and women. Figure template from http://yourfreetemplates.com (see “Details for preparation of Figure 1” in the Online Appendix). ACC/AHA, American College of Cardiology/American Heart Association; CHA2DS2-VASc, Congestive Heart Failure, Hypertension, Age ≥75 Years, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack or Thromboembolism, Vascular Disease, Age 65 to 74 Years, Sex; CUORE, Continuous Ultrafiltration for Congestive Heart Failure; FC-IHRS, fasting cholesterol INTERHEART risk score; INTERHEART, Effect of Potentially Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries; NL-IHRS, nonlaboratory INTERHEART risk score; PROCAM, Prospective Cardiovascular Münster.
included population-based samples [20,21,24,25], whereas the other one-half included people that were somehow affiliated with health care facilities [19,22,23,26]. For example, Muñoz et al. [22] included individuals who attended a primary prevention clinic at the Central Military Hospital in Colombia. Likewise, Acevedo et al. [19] enrolled individuals who voluntarily attended a cardiology prevention program in Chile. Women accounted for more than one-half of the study population in 5 reports [20-23,25]; in 1 report the women-to-men ratio was 1 [26]; and in 2 reports, men accounted for a larger share of the study population [19,24]. Although it was not possible to extract baseline age information from 1 study [20], the others had either a mean of, or a larger proportion of, people ≥50 years old [19,22-26]; in the report by Jimenez-Corona et al. [21], the mean age was 47 years.

Across the studies summarized herein, the mean sample size was 16,310 (SD: 37,107.4). Sample size was over 1,000 people in 7 of the studied reports, and 1 report included 468 individuals [26]. The largest sample sizes were from multi-country endeavors [20,25]. The only study conducted in the Caribbean in the mid-1960s also had a large sample size (n = 8,713) [24]. One study did not report follow-up time duration [25], and another reported 10 years of follow-up or censoring/event [22]; in general, follow-up time ranged from 12 ± 4 months [26] to 9.2 ± 2.1 years [23].

Most reports included the same outcomes as those of the original prognostic model being studied (e.g., Framingham model); however, although the original model included both nonfatal and fatal cardiovascular events, 1 report could only analyze the latter [19]. All reports included some predictors of the original model, and these were assessed following standard procedures such as clinical examination or laboratory tests. Further details about the characteristics of the summarized reports, including methods for predictors and outcomes ascertainment, are shown in Table 2 and the Extraction Form in the Online Appendix.

**Cardiovascular prognostic models**

**Characteristics.** None of the reviewed reports developed a prognostic model for cardiovascular events based on LAC populations; conversely, reviewed reports tested available prognostic models [19,21-23,26] and some of them pursued recalibration strategies [20,24,23].

The most frequently studied prognostic model was the Framingham risk prediction equation (6 times) [19-24], followed by the American College of Cardiology/American Heart Association Pooled Cohorts Equation (2 times) [19,20]; all other prognostic models were studied once: the nonlaboratory INTERHEART (Effect of Potentially Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries) risk score and the fasting cholesterol INTERHEART risk score [25]; Globorisk [20]; CUORE (Continuous Ultrafiltration for Congestive Heart Failure) [20]; PROCAM (Prospective Cardiovascular Munster) [22]; and CHA2DS2-VASc (Congestive Heart Failure, Hypertension, Age ≥75 Years, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack or Thromboembolism, Vascular Disease, Age 65 to 74 Years, Sex) [26].

Most reports studied prognostic models with few outcome events per predictor. One study had 352 outcome events [25], and in 6 reports this figure ranged from 15 [26] to 72 [23] (Table 2). In addition, none reported a formal sample size estimation or whether the number of outcome events was adequate given the number of predictors.

Missing data was handled by conducting a complete-case analysis in 5 reports [20,21,23,25,26], only 1 conducted multiple imputation [22], and 2 did not provide information about this matter [19,24]. Only 1 of the reviewed reports conducted bootstrap analysis to compute the confidence intervals of the area under the receiver operator curve [19].

**Performance.** Most reports provided estimates of calibration and discrimination [20,22-25]; 2 also reported classification metrics such as positive/negative likelihood ratio [20,26]. Calibration and discrimination estimates are presented in Table 3 and Figure 1 (Online Table 1). Although all discrimination estimates (e.g., C-statistics) were reported with wide confidence intervals, the highest discrimination metric achieved was for the American College of Cardiology/American Heart Association (ACC/AHA) pooled risk equation by Acevedo et al. [19]; however, they did not include all the outcomes of the original model so that this estimate should be interpreted cautiously.

**Risk of bias**

In the participants, predictors, and outcome domains of the risk of bias, all the reports were deemed to be of low risk; the outcomes were clearly defined and agreed with those of the original model except for 1 study that addressed the American College of Cardiology/American Heart Association Pooled Cohorts Equation [19]. The fourth criteria—analysis—was troublesome for the reviewed reports largely because the few number of outcome events, yielding a limited outcome-predictors ratio, and for conducting complete-case analysis rather than multiple imputation process. A summary of the risk of bias analysis is shown in Table 4, and details on each criterion across domains are provided in Risk of Bias (PROBAST) in the Online Appendix.

**DISCUSSION**

**Summary of evidence**

Although cardiovascular prognostic models have been summarized by global systematic reviews, none of them found models or efforts undertaken in, and for, LAC populations [9,10]. This work complements these reviews with evidence from LAC and clearly demarcates that there is scope for the improvement of cardiovascular risk prediction in the LAC region. Eight studies were selected for
### TABLE 2. Methodological characteristics of the reviewed prognostic models

| Study, Year (Ref. #) | Predictors Ascertainment | Outcome Details | Outcome Ascertainment | Mean Follow-Up (yrs)* | Baseline Sample | Outcome Events | Original Prediction Model Being Tested |
|----------------------|---------------------------|-----------------|-----------------------|-----------------------|-----------------|---------------|----------------------------------------|
| Polenz, 2015 [26]    | Two physicians independently performed clinical assessment and reviewed electronic medical records. | All-cause mortality, stroke, transient ischemic attack, acute myocardial infarction, and new atrial fibrillation/flutter. | A specialist validated each outcome (e.g., stroke by a neurologist). | 1.3 (12 ± 4 months) | 468 | 15 | CHA2DS2-VASC |
| Muñoz, 2014 [22]     | A researcher extracted all the information from health records. | Total coronary disease: coronary death; myocardial infarction; angina pectoris, coronary insufficiency. Hard coronary disease: coronary death and myocardial infarction. | By a researcher who did not have access to baseline information. Health records of people suspected to have had a coronary event were verified by an internal medicine physician, who defined whether these were either total or hard coronary diseases. Cause of death was based on death certificates or discharge records. | 10 yrs, event or censoring | 1,013 | 61 | Framingham, PROCAM |
| Gulayin, 2018 [20]   | Blood pressure, measured after a 5-min rest using a mercury or aneroid sphygmomanometer; average of 3 readings was used. Blood samples were withdrawn after ≥10 h of fasting. | Angina pectoris, nonfatal/fatal myocardial infarction, nonfatal/fatal stroke, coronary artery, carotid or peripheral revascularization, heart failure, and sudden death. | Events were confirmed by an internal medicine or cardiology specialist after verification of the event-specific record. | Median = 2.2 (IQR: 1.9–2.8) | 6,364 | 60 | CUORE, Framingham, Globorisk, ACC/AHA Pooled Equation |

(continued)
| Study, Year (Ref. #) | Predictors Ascertainment | Outcome Details | Mean Follow-Up (yrs)* | Baseline Sample | Outcome Events | Original Prediction Model Being Tested |
|----------------------|--------------------------|-----------------|-----------------------|----------------|---------------|--------------------------------------|
| Sandoya, 2009 [23]   | Interviews for smoking and medication use. Blood pressure measured with a semi-automatic validated instrument during a resting period, using the mean of 3 measurements separated at least 2 min. Blood samples were withdrawn after a 12-h fasting period and analyzed in a central laboratory. | Ischemic disease as ICD-10—l21, l20, l20.9, l46—or revascularization. Based on discharge diagnosis on medical records, when needed telephone communications were held with the participants or relatives. | 9.2 ± 2.1 | 1,110 | 72 | Framingham |
| Acevedo, 2017 [19]   | Blood samples withdrawn after a 12-h fasting period from venous samples. All participants were interviewed. Blood pressure was measured according to JNC VII. | Nonfatal/fatal myocardial infarction, nonfatal/fatal stroke, or other cardiovascular event. Deaths registries were obtained. No information on ascertainment of nonfatal events; it is reported that the analyses were based on mortality as the outcome (cardiovascular mortality). | 7 ± 3 | 3,284 | 34 | ACC/AHA Pooled Equation; Framingham and Framingham Chileno. |
| Jiménez-Corona, 2009 [21] | Standard questionnaires were used. Blood pressure was measured 3 times after a 5-min rest using a random 0 sphygmomanometer; the mean of the last 2 records was used. Fasting serum total cholesterol and HDL were determined by cholesterol-esterase. | Nonfatal/fatal myocardial infarction. By resting ECG or by death certificate. ECG were interpreted according to the Minnesota code, including possible and probable myocardial infarctions. Death certificates in which the underlying cause of death was ICD-10 410—410.9. | Median = 6.2 (range 0.2—9.8) | 1,667 | 58 | Framingham by Wilson et al., and by Anderson et al. |
| Name          | Study Description | Cause of Death                                    | Event Definition                                                                 | Event Rate | Sample Size  | Study Type       |
|--------------|------------------|--------------------------------------------------|----------------------------------------------------------------------------------|------------|--------------|------------------|
| Joseph, 2018 | No details provided. | Cardiovascular death, myocardial infarction, stroke, heart failure, or revascularization (percutaneous coronary intervention or coronary artery bypass). | Participants or relatives were interviewed for cardiovascular events. All events were reviewed at each study site using supporting documentation, verbal autopsies, or medical records; standard definitions were used. | 4.89 (2.24) | 100,475 (NL-IHRS) 107,863 (FC-IHRS) | NL-IHRS and FC-IHRS |
| D’Agostino, 2001 | No details provided. | Coronary death or myocardial infarction. | No details provided. | 8,713 | No details provided. | Framingham |

ACC/AHA, American College of Cardiology/American Heart Association; CHA2DS2-VASc, Congestive Heart Failure, Hypertension, Age ≥75 Years, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack or Thromboembolism, Vascular Disease, Age 65 to 74 Years, Sex; CUORE, Continuous Ultrafiltration for Congestive Heart Failure; ECG, electrocardiography; FC-IHRS, fasting cholesterol INTERHEART risk score; HDL, high-density lipoprotein; ICD-10, International Classification of Diseases, 10th revision; INTERHEART, Effect of Potentially Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries; IQR, interquartile range; JNC VII, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NL-IHRS, nonlaboratory INTERHEART risk score; PROCAM, Prospective Cardiovascular Münster.

*Unless otherwise indicated.
| Study, Year, Ref. # | Calibration | Discrimination | Classification Measures |
|---------------------|-------------|----------------|-------------------------|
| Polenz, 2015 [26]   | No details provided. | C-statistic = 0.62 (95% CI: 0.58–0.67) | At a score of ≥6 points + LR = 3.45, −LR = 0.78, sensitivity = 28.6, specificity = 91.7 for the occurrence of stroke or TIA; +LR = 3.35, −LR = 0.79, sensitivity = 27.3, specificity = 91.9 for stroke, TIA, and death. |
| Muñoz, 2014 [22]    | Framingham: overestimation; for people at low and intermediate risk, the relationship between expected and observed was 1.31; for people at high risk, the absolute difference between the proportion of expected and observed events was 17.4. PROCAM: similar findings for all risk groups; for people at low and intermediate risk the absolute difference between percentages of expected and observed events was <3%; poor calibration (overestimation) for people at high risk. PROCAM adjusted for sex (so that can be used in men and women) showed similar calibration properties. | Framingham: AUC = 0.6584 (95% CI: 0.6258–0.6907). PROCAM: AUC = 0.5819 (95% CI: 0.5238–0.6385). PROCAM adjusted for sex: AUC = 0.7446 (95% CI: 0.7142–0.7740). | No details provided. |
| Gulayin, 2018 [20]  | They reported the $\hat{\beta}$ slope for calibration. CUORE: $y = 1.012x - 0.0036$. Framingham: $y = 1.0956x - 0.014$. Globorisk: $y = 1.3718x - 0.0066$. ACC/AHA pooled equation: $y = 0.5103x + 0.0095$. | CUORE: C-statistic = 0.751 and Harrell’s C index = 0.752. Framingham: C-statistic = 0.719 and Harrell’s C index = 0.722. Globorisk: C-statistic = 0.753 and Harrell’s C index = 0.736. ACC/AHA pooled equation: C-statistic = 0.736 and Harrell’s C index = 0.743. | CUORE: sensitivity = 73% and specificity = 69%. Framingham: sensitivity = 81% and specificity = 51%. Globorisk: sensitivity = 75% and specificity = 60%. ACC/AHA pooled equation: sensitivity = 75% and specificity = 58%. |
| Sandoya, 2009 [23]  | Hosmer-Lemeshow for men was 6.82 ($p = 0.56$) and for women was 5.09 ($p = 0.64$). | AUC for men was 0.76 (95% CI: 0.69–0.82) and for women was 0.67 (95% CI: 0.56–0.78). | No details provided. |
| Acevedo, 2017 [19]  | No details provided. | ACC/AHA pooled equation: AUC = 0.78 (95% CI: 0.68–0.84). Framingham: AUC = 0.60 (95% CI: 0.52–0.74). Framingham Chileno: AUC = 0.67 (95% CI: 0.60–0.79). | No details provided. |
| Study                                      | Details                                                                 |
|--------------------------------------------|-------------------------------------------------------------------------|
| Jiménez-Corona, 2009 [21]                 | The ratio of predicted/observed rates using the first equation (Framingham by Wilson et al.) was 1.84 (95% CI: 1.15–2.53) in men and 1.55 (95% CI: 1.01–2.08) in women; the ratio using the second equation (Framingham by Anderson et al. [27]) was 3.17 (95% CI: 1.67–4.68) in men and 1.57 (95% CI: 1.67–2.17) in women. |
| Joseph, 2018 [25]                          | Original NL-IHRS: slope = 0.87 (0.77–0.98), intercept = −4.43 (−4.75 to 4.29); for the recalibrated version these parameters were 1 (0.87–1.13) and 0 (−0.48 to 0.48). Original FC-IHRS: slope = 1.11 (0.97–1.24), intercept = −4.35 (−4.49 to 4.21); for the recalibrated version these parameters were 1 (0.88–1.12) and 0 (−0.45 to 0.45). |
| D’Agostino, 2001 [24]                      | Best chi-square using the Puerto Rico study’s means on the risk factors and the Puerto Rico study’s CHD incidence = 7.2. In Hispanic population, the best Cox (applying the Cox model developed on the Puerto Rico study’s data): C-statistic = 0.72. |

AUC, area under the curve; CHD, coronary heart disease; CI, confidence interval; LR, likelihood ratio; TIA, transient ischemic attack; other abbreviations as in Table 2.
TABLE 4. Risk of bias assessment

| Study, Year   | Participants | Predictors | Outcome | Analysis | Participants | Predictors | Outcome | Risk of Bias | Applicability | Overall |
|---------------|--------------|------------|---------|----------|--------------|------------|---------|--------------|--------------|---------|
| Polenz, 2015  | Low          | Low        | Low     | High     | High         | Low        | Low     | High         | Low          | High    |
| Muñoz, 2014   | Low          | Low        | Low     | High     | High         | Low        | Low     | High         | Low          | High    |
| Gulayin, 2018 | Low          | Low        | Low     | High     | Low          | Low        | High    | Low          | Low          | Low     |
| Sandoya, 2009 | Low          | Low        | Low     | High     | High         | Low        | Low     | High         | High         | High    |
| Acevedo, 2017 | Low          | Low        | High    | High     | Low          | Low        | Low     | High         | High         | High    |
| Jiménez-Corona, 2009 | Low         | Low        | Low     | High     | Low          | Low        | High    | High         | High         | High    |
| Joseph, 2018  | Low          | Low        | Low     | High     | Low          | Low        | Low     | Low          | Low          | Low     |
| D’Agostino, 2001 | Low       | Low        | Low     | High     | Low          | Low        | Low     | Low          | Low          | Low     |

PROBAST, Prediction model Risk Of Bias ASsessment Tool.
In the risk of bias assessment, low means low risk of bias, high means high risk of bias, and unclear when it was not possible to assess the risk of bias. In the applicability section, high means high concern for applicability, low means low concern for applicability, and uncertain when it was not possible to assess the applicability. Risk of bias conducted with the PROBAST tool [16-18].

Qualitative synthesis: none developed a prognostic model, only 1 was conducted in the Caribbean [24], and many have major limitations with regards to sample size and analysis, for example, limited number of outcome events. The Framingham and the American College of Cardiology/American Heart Association Pooled Cohorts Equation were the most studied tools. Calibration estimates changed substantially from one population to another, with serious overestimation in some cases, that is, individuals categorized as high risk when they were not. Discrimination was acceptable in many reports, particularly for the American College of Cardiology/American Heart Association Pooled Cohorts Equation. Based on these findings, and the heterogeneous health profile of LAC populations, it is premature to strongly advocate for 1 prognostic model in LAC.

Limitations at study level
Most studies analyzed few outcome events, which could account for wide confidence intervals, but most importantly for lack of power to make strong conclusions. Just recently, new approaches for estimating sample size or adequate number of events per predictor in the prognostic models have been proposed [28,29]. Future cardiovascular prognostic work could formally test these requirements. Joseph et al. [25] conducted the work with the “largest” outcome events per predictor ratio (ratio = 16). Nonetheless, and even though they had a model without laboratory variables, the model had over 20 predictors, which would make it troublesome to use in the field because it will require much information. In addition, some of the predictors were about diet profile [25], which could require further knowledge about local foods, hence making these questions difficult to ascertain.

It seemed that the reviewed studies made a great effort to conduct follow-up rounds and to accurately capture the outcomes of interest; however, 1 study could not adjudicate nonfatal outcomes even though the model being evaluated needed them [19]. This highlights the necessity for national health registries, at least of major events of noncommunicable diseases. These could inform health authorities, as well as researchers who will ultimately provide evidence to advise public health and clinical practice.

Strengths and limitations at the review level
The research question and search strategy were defined following international guidelines for systematic reviews of prognostic models [13,14]. The search terms were based on previous systematic reviews and followed recommendations for finding prognostic studies [9,10,30]. In addition, risk of bias was formally assessed with a validated tool [16-18]. Nevertheless, this work is subject of several limitations. First, given the results about heterogeneity and the low number of reviewed reports, a quantitative summary (e.g., meta-analysis) was not be conducted. Second, we could have further reviewed gray reports, such as graduate programs dissertations of LAC universities. Although this could have retrieved more results, we doubt these would have been of greater quality than the published works herein analyzed. Therefore, we would have still not reached a strong recommendation for (or against) a given prognostic model.

Other relevant publications
To summarize the strongest evidence on prognostic research we focused on prospective studies. Nonetheless, it seemed fair to also acknowledge other endeavors in LAC that, despite following different study designs, have still provided relevant evidence.

For example, Icaza et al. [31] adapted the Framingham equation using population-based estimates on risk factors and incidence of cardiovascular events based on national registries in Chile. This work has informed clinical and research practice in Chile. More recently, a population-based cohort was initiated in Maule, Central Chile. The MAUCO (Maule Cohort) study aims to enroll 10,000 people from 3 to 74 years old who will be followed for at
least 10 years, with outcome measurements focused on cardiovascular diseases and cancer. The prospective design of MAUCO offers a unique opportunity to develop local prognostic models for the Chilean population [32]. Similar efforts in Peru and Argentina may provide solid evidence for these countries [33,34], though a regional approach will still be missing.

The systematic search yielded 1 additional work from Central America. This was a bold project that attempted to generate a new prognostic model for myocardial infarction using case-control data from Costa Rica [35]. Despite the design limitations, they included a key item among their predictors: socioeconomic status. This relevant health determinant has been systematically excluded from many prognostic models, though just recently it has been highlighted by a novel model developed for New Zealand [36]. LAC is a region with large socioeconomic inequalities, and their effect on cardiovascular outcomes may be important. Therefore, should a new cardiovascular prognostic model be developed for LAC, a marker of socioeconomic status should be at least tested among other potential predictors.

Although gray reports were beyond the scope of our search, a master’s dissertation was also retrieved by our search strategy; the outcome was coronary artery disease and included 349 individuals in Brazil [37]. This work included genetic predictors [37], which although relevant and research on this field should be fostered, it is perhaps premature to have prognostic models with predictors that are not widely available.

Finally, the Globorisk investigators developed cardiovascular risk charts for 182 countries including those in LAC [38,39]. Even though this was an example of global collaboration and comprehensive research methods, the risk charts were developed using risk prediction associations (e.g., hazard ratios) from cohorts mostly in the United States. This may limit the applicability of this model to other world regions including LAC, calling for updates to this and other models with weights (i.e., hazard estimates) retrieved from LAC studies.

Research gaps
This review identified a lack of cardiovascular prognostic models developed in and for LAC populations, which needs urgent attention. Research funders, along with regional and local health authorities, should support new or ongoing prospective cohort studies to address this gap. This does not necessarily mean establishing a new multi-country or region-wide cohort but supporting further follow-up rounds of existing cohorts, particularly of population-based cohorts. In addition, regional and local health authorities could work to facilitate access to national health/death registries for research purposes. This way, large cross-sectional epidemiological studies and surveys could access data on cardiovascular nonfatal and fatal outcomes, in other words, entering the world of health big data in LAC. In the meantime, cohort data pooling may be a feasible solution.

Another relevant research gap observed by this review is the dearth of studies from the Caribbean and Central America regions. Besides a case-control study (Costa Rica) [33] and a prospective cohort, the baseline assessment of which was in the 1960s (Puerto Rico) [24], no additional results were retrieved for these regions. This calls for investigators to strengthen local research capacity and to generate, reuse, or update available cohorts in the Caribbean and Central America.

In terms of methods, this review found that 1 study followed multiple imputation to account for missing data; also, there were a low number of outcome events and some predictors were categorized when they could have been used as continuous variables [40,41]. These methodological approaches could hide a lack of training or expertise in validation (and development) of prognostic models. Despite abundant methodological evidence (e.g., statistical primers [42] and reviews [43-46]) on prognosis models, these are mostly in English, which could be a limitation for some researchers in LAC. In terms of capacity building, existing training programs in epidemiology and related fields should include prognostic research methods.

Reporting was also heterogeneous across studies. It would be impossible for studies published before 2015 to have adhered to the TRIPOD statement [47], but neither did the post-2015 papers. This again calls for investigators to improve prediction research capacity in LAC.

Implications for public health
Where poor-quality health care could be worse than any health care [48], the health system should secure adequate interventions to prevent diseases and complications. This ranges from highly complex treatments to prevention strategies. Among the latter, estimating the absolute risk of an event might guide the allocation of treatment and preventive measures in favor of high-risk individuals. However, if prediction tools are not accurate enough, people who do not need treatment would unnecessarily receive medication and people who need it would not be identified. Considering this systematic review, local and regional health authorities, researchers, and practitioners should understand the pitfalls of using available cardiovascular prognostic models in LAC and procure the development, comprehensive validation, or adequate recalibration of available models.

Implications for clinical practice
Several international societies and clinical guidelines have signaled the need to guide cardiovascular treatment and other prevention interventions based on absolute risk for which prognostic models are paramount [27,49-54]. In particular, risk stratification based on these models contribute to allocation of health resources in a cost-effective manner, allowing individuals with higher global risk to receive adequate treatment and avoiding overtreatment in individuals at low risk [27,49-54].
In Chile, the tables of cardiovascular risk stratification adapted by Icaza et al. [31] were adopted by the Ministry of Health and have been used in the public primary health system since 2009 [54]. In 2013, Kunstmann et al. [55] conducted a validation of the Chilean tables, confirming that they are useful in the prediction of coronary and cerebrovascular events. Therefore, the Chilean tables continue to be used to estimate the global risk of cardiovascular diseases at individual level in Chile [55].

The fact that no cardiovascular prognostic models have been developed in LAC, and the fact that attempts to test the accuracy of available prognostic models in LAC have faced several limitations, puts LAC in a disadvantaged position to successfully lessen the burden of cardiovascular diseases. This review could not strongly recommend any available prognostic model to be used across LAC settings. Notwithstanding, acknowledging their limitations, weighing the pros and cons, and reaching an informed decision with the patient, country-specific models could be used after adequate recalibration.

CONCLUSIONS
No cardiovascular prognostic model has been developed in or for the LAC region. The evaluation of available prognostic models signals to several limitations, and their prediction accuracy is questionable particularly regarding calibration, albeit discrimination was acceptable in most cases. Advancement of cardiovascular prognosis research might contribute to improve the allocation of scarce resources to people who need them the most, thus fostering the prevention of cardiovascular diseases in this world region and to achieve this goal, appropriate cardiovascular risk prediction is needed in the LAC region.

ACKNOWLEDGMENT
The authors thank Jahanna A.A.G. Damen for providing additional material of a previous global systematic review useful for this work.

REFERENCES
1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151–210.
2. GBD 2016 DALYs and HEALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1260–344.
3. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32–8.
4. Rose G. Sick individuals and sick populations. Int J Epidemiol 2001;30:427–32. discussion 433–4.
5. Karmali KN, Peresl SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887.
6. Usher-Smith JA, Silvarava B, Schuit E, Moons KG, Griffin SJ. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open 2015;5:e008717.
7. Cortes-Bergoderi M, Thomas RJ, Albuquerque FN, et al. Validity of cardiovascular — risk prediction models in Latin America and among Hispanics in the United States of America: a systematic review. Rev Panam Salud Publica 2012;32:131–9.
8. Carrillo-Larco RM, Barengo NC, Albitres-Flores L, Bernabe-Ortiz A. The risk of mortality among people with type 2 diabetes in Latin America: A systematic review and meta-analysis of population-based cohort studies. Diabetes Metab Rev Res 2019 Feb 13 [E-pub ahead of print].
9. Beswick AD, Brindle P, Fahey T, Ebrahim S. National Institute for Health and Clinical Excellence: Guidance. A Systematic Review of Risk Scoring Methods and Clinical Decision Aids Used in the Primary Prevention of Coronary Heart Disease (Supplement). London, UK: Royal College of General Practitioners (UK) Royal College of General Practitioners; 2008.
10. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 2016;353:i2416.
11. Carrillo-Larco RM, Pacheco-Barrios N, Altez-Fernandez C. Risk prediction tools for cardiovascular diseases in Latin America and the Caribbean: a systematic review of prognostic models. PROSPERO 2018 CRD42018096553. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018096553. Accessed January 4, 2019.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
13. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 2014;11:e1001744.
14. Debray TP, Damen JA, Snell KJ, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ 2017;356:i4660.
15. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5:210.
16. Wolff R, Moons K, Riley RD, et al. PROBAST Group. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med 2019;170:51–8.
17. Wolff R, Whiting P, Mallett S, et al. PROBAST: a risk of bias tool for prediction modelling studies. Paper presented at: 23rd Annual Cochrane Colloquium; October 3–7, 2015; Vienna, Austria.
18. Moons KGM, Wolf F, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med 2019;170:W1–33.
19. Acevedo M, Valentino G, Kramer V, et al. Superioridad del nuevo puntaje de riesgo ACC/AHA 2013 por sobre el puntaje de Framingham, en la predicción de riesgo de mortalidad cardiovascular en Santiago [Evaluation of the American College of Cardiology and American Heart Association predictive score for cardiovascular diseases]. Rev Med Chil 2017;145:292–8.
20. Gulayin PE, Danaei G, Gutierrez L, et al. External validation of cardiovascular risk scores in the southern cone of Latin America: Which predicts better? Rev Argentina Cardio 2018;86:13–8.
21. Jimenez-Corona A, Lopez-Ridaura R, Williams K, et al. Applicability of Framingham risk equations for studying a low-income Mexican population. Salud Publica Mex 2009;51:298–305.
22. Muñoz OM, Rodríguez NI, Ruiz A, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol 2014;21:202–12.
23. Sandoya EA, Schwedt Celiberti EC, Moreira MV, Schettini C, Bianchi M, Senra H. Predicción de eventos coronarios a nueve años mediante el score de Framingham en Uruguay. Rev. Urug. Cardiol 2009;24:13–21.
24. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180–7.
25. Joseph P, Yuaf S, Lee SF, et al. PURE Investigators. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart 2018;104:581–7.

26. Polenz GF, Leiria TTL, Essebag V, et al. CHA2DS2 VASc score as a predictor of cardiovascular events in ambulatory patients without atrial fibrillation. Pacing Clin Electrophysiol 2015;38:1412–7.

27. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016;32:1263–82.

28. Riley RD, Snell KIE, Enser J, et al. Minimum sample size for developing a multivariable prediction model: part I—continuous outcomes. Stat Med 2019;38:1262–75.

29. Riley RD, Snell KIE, Enser J, et al. Minimum sample size for developing a multivariable prediction model: part II—binary and time-to-event outcomes. Stat Med 2019;38:1276–96.

30. Geersing GJ, Bouwmeester W, Zuiithoff P, Spijker R, Leeflang M, Moons KG. Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews. PLoS One 2012;7:e32444.

31. Icaza G, Núñez L, Marrugat J, et al. Estimación de riesgo de enfermedad coronaria mediante la función de Framingham adaptada para la población chilena [Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations]. Rev Méd Chil 2009;137:1273–82.

32. Ferreccio C, Roa JC, Bambs C, et al. Study protocol for the Maule Cohort (MAUCO) of chronic diseases, Chile 2014—2024. BMC Public Health 2016;16:122.

33. Miranda JJ, Bernabe-Ortiz A, Smeeth L, Gilman RH, Checkley W. Addressing geographical variation in the progression of non-communicable diseases in Peru: the CRONICAS cohort study protocol. BMJ Open 2012;2:e000610.

34. Rubinstein AL, Irazola VE, Poggio R, et al. Detection and follow-up of cardiovascular disease and risk factors in the Southern Cone of Latin America: the CESCAS study. BMJ Open 2011;1:e000126.

35. Aslibekyan S, Campos H, Loucks EB, Linkletter CD, Ordovas JM, Baylin A. Development of a cardiovascular risk score for use in low- and middle-income countries. J Nutr 2011;141:1375–80.

36. Pylpuchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400,000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391:1897–907.

37. Mendes VHP. Determinantes genéticos de doença arterial coronária em uma amostra da população brasileira [dissertação]. São Paulo, Brazil: Universidade de São Paulo, Faculdade de Medicina. 2015. Available at: http://www.teses.usp.br/teses/disponiveis/5/5156/tde-24032016-151945/. Accessed September 10, 2018.

38. Hajifathalian K, Ueda P, Lu Y, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015;3:339–55.

39. Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol 2017;5:196–213.

40. Steyerberg EW, Uno H, loannids JP, van Calster B. Poor performance of clinical prediction models: the harm of commonly applied methods. J Clin Epidemiol 2018;98:133–43.

41. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol 2016;76:175–82.

42. Grant SW, Collins GS, Nashel SAM. Statistical Primer: developing and validating a risk prediction model. Eur J Cardiothorac Surg 2018;54:203–8.

43. Wynnants L, Collins GS, Van Calster B. Key steps and common pitfalls in developing and validating risk models. BIOG 2017;124:423–32.

44. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012;98:683–90.

45. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012;98:691–8.

46. Steyerberg EW, Vergouw E. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 2014;35:1925–31.

47. Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1–73.

48. Kruk ME, Gage AD, Joseph NT, Danaei G, Garcia-Saiso S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 2018;392:2203–12.

49. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts), developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.

50. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–934.

51. World Health Organization. WHO Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Geneva, Switzerland: World Health Organization; 2007.

52. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365:434–41.

53. National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. Lipid modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London, UK: National Institute for Health and Care Excellence; 2014.

54. Ministerio de Salud, Gobierno de Chile. Consenso MINSAL Chile 2014 Enfoque de riesgo para la prevención de enfermedades cardíacas. Available at: http://www.enfermeriassoc.com/portal/consenso-minsal-chile-2014-enfoque-de-riesgo-para-la-prevencion-de-enfermedades-cardiovasculares. Accessed January 4, 2019.

55. Kunstmann S, Gainza IF. Herramientas para la estimación del riesgo cardiovascular. Rev Méd Clin Las Condes 2018;29:6–11.